PHAR - Pharming Group Nv
NYSE * Health Care * Biotechnology
$13.62
+$1.02 (+8.10%)
About Pharming Group Nv
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
PHAR Key Statistics
Market Cap
$961.21M
P/E Ratio
71.63
P/B Ratio
3.31
EPS
$0.19
Revenue Growth
-0.1%
Profit Margin
0.0%
Employees
407
How PHAR Compares to Peers
P/E Rank
#6
of 6
Margin Rank
#6
of 6
Growth Rank
#6
of 6
Size Rank
#6
of 6
Pharming Group Nv Company Information
- Headquarters
- Netherlands
- Website
- www.pharming.com
- Sector
- Health Care
- Industry
- Biotechnology